Addex Therapeutics Ltd ADR (ADXN)

Overview News Price History Discussions Forecast Stock Split

Addex Therapeutics Ltd ADR stock is currently priced at $20.05, with a 24-hour trading volume of 19,537. It has seen a -4.34% decreased in the last 24 hours and a +66.60% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $22.08 pivot point. If it approaches the $19.48 support level, significant changes may occur.

Addex Therapeutics Ltd ADR Stock (ADXN) Financials Data

Addex Therapeutics Ltd ADR (ADXN) Revenue 2024

ADXN reported a revenue (TTM) of $2.23 million for the quarter ending September 30, 2023, a +71.24% rise year-over-year.

Addex Therapeutics Ltd ADR (ADXN) Net Income 2024

ADXN net income (TTM) was -$12.33 million for the quarter ending September 30, 2023, a +46.00% increase year-over-year.

Addex Therapeutics Ltd ADR (ADXN) Cash Flow 2024

ADXN recorded a free cash flow (TTM) of -$11.75 million for the quarter ending September 30, 2023, a +31.49% increase year-over-year.

Addex Therapeutics Ltd ADR (ADXN) Earnings per Share 2024

ADXN earnings per share (TTM) was -$19.59 for the quarter ending September 30, 2023, a +72.50% growth year-over-year.

Addex Therapeutics Ltd ADR Stock (ADXN) Latest News

Addex to Present at the Swiss Biotech Day 2024

GlobeNewswire Inc.

Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire Inc.

Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

Why Macatawa Bank Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket

Benzinga

Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024

GlobeNewswire Inc.

Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket

Benzinga

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.